Finding your next opportunity shouldn’t require piecing together multiple databases, alerts and research tools.
Fundz combines its own funding and M&A intelligence with hiring, leadership and other business signals into one connected view of each company, ranks opportunities against your ideal customer profile, and delivers the evidence and verified contacts to act on. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Moleculin Biotech, Inc.
The company shared information publicly (Regulation FD). An 8-K is the notice a US public company must file within four business days of a major event.
moleculin.comAI Executive Summary
AI-powered analysis of 8-K filing content
Moleculin Biotech announced promising preclinical data showing that its lead drug candidate Annamycin demonstrates antitumor activity in pancreatic cancer, partially mediated by CD8+ T cell cytotoxicity. This data presentation at a major oncology conference strengthens the company's competitive positioning in the oncology market.
Key Takeaways
Annamycin (naxtarubicin) shows antitumor activity in pancreatic cancer through CD8+ T cell-mediated cytotoxicity mechanism
Findings are being presented at the AACR Conference on Pancreatic Cancer (September 25-28, 2026) in San Diego, providing third-party validation
1 more takeaway
Filing Overview
What This Means
Moleculin Biotech, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.